Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 23;25(8):307.
doi: 10.31083/j.rcm2508307. eCollection 2024 Aug.

Outcome of Transcatheter Aortic Valve Replacement for Pure Native Aortic Regurgitation in Patients with Pulmonary Hypertension

Affiliations

Outcome of Transcatheter Aortic Valve Replacement for Pure Native Aortic Regurgitation in Patients with Pulmonary Hypertension

Da-Wei Lin et al. Rev Cardiovasc Med. .

Abstract

Background: In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a pivotal treatment for pure native aortic regurgitation (PNAR). Given patients with severe aortic regurgitation (AR) are prone to suffer from pulmonary hypertension (PH), understanding TAVR's efficacy in this context is crucial. This study aims to explore the short-term prognosis of TAVR in PNAR patients with concurrent PH.

Methods: Patients with PNAR undergoing TAVR at Zhongshan Hospital, Affiliated with Fudan University, were enrolled between June 2018 to June 2023. They were categorized based on pulmonary artery systolic pressure (PASP) into groups with or without PH. The baseline characteristics, imaging records, and follow-up data were collected.

Results: Among the 103 patients recruited, 48 were afflicted with PH. In comparison to PNAR patients without PH, the PH group exhibited higher rates of renal dysfunction (10.4% vs. 0.0%, p = 0.014), increased Society of Thoracic Surgeons scores (6.4 ± 1.9 vs. 4.7 ± 1.6, p < 0.001), and elevated Nterminal fragment of pro-brain natriuretic peptide (NT-proBNP). Transthoracic ultrasound examination revealed that patients with PH displayed lower left ventricular ejection fraction, larger left ventricle dimension, and more frequent moderate to severe tcuspid regurgitation (TR). Following TAVR, both groups experienced significant reductions in PASP, mitral regurgitation (MR) and TR. There were no significant differences in the incidence of postoperative adverse events in patients with or without PH.

Conclusions: We found TAVR to be a safe and effective treatment for patients with PNAR and PH, reducing the degree of aortic regurgitation and PH without increasing the risk of postoperative adverse events.

Keywords: pulmonary artery hypertension; pure native aortic regurgitation; retrospective; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Changes in the NYHA functional classification in PNAR patients Pre- and Post-TAVR, with and without PH. Assessment of the NYHA functional class changes in patients with PNAR undergoing TAVR, categorized by the presence or absence of PH. (A) illustrates the progression in patients without PH, while (B) details those with PH. These comparisons highlight the procedural impact on cardiac functional status over the follow-up period. Abbreviations: PH, pulmonary artery hypertension; TAVR, transcatheter aortic valve replacement; NYHA, New York Heart Association; PNAR, pure native aortic regurgitation.
Fig. 2.
Fig. 2.
Changes in PASP pre- and post-TAVR in PNAR patients, segregated by PH status. Comparison of PASP before and after TAVR in patients with PNAR, differentiated by the absence (A) or presence (B) of PH. The figure underscores the procedural impact on PASP across both patient categories over the follow-up period, demonstrating the effectiveness of TAVR in modifying hemodynamic parameters. Abbreviations: PH, pulmonary artery hypertension; TAVR, transcatheter aortic valve replacement; PASP, systolic pulmonary artery pressure; PNAR, pure native aortic regurgitation.

Similar articles

References

    1. Jilaihawi H, Chen M, Webb J, Himbert D, Ruiz CE, Rodés-Cabau J, et al. A Bicuspid Aortic Valve Imaging Classification for the TAVR Era. JACC. Cardiovascular Imaging . 2016;9:1145–1158. - PubMed
    1. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) The American Journal of Cardiology . 1999;83:897–902. - PubMed
    1. Markham R, Ghodsian M, Sharma R. TAVR in Patients with Pure Aortic Regurgitation: Ready to Use? Current Cardiology Reports . 2020;22:98. - PubMed
    1. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation . 1999;99:1851–1857. - PubMed
    1. Tarasoutchi F, Grinberg M, Spina GS, Sampaio RO, Cardoso LUF, Rossi EG, et al. Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology. Journal of the American College of Cardiology . 2003;41:1316–1324. - PubMed

LinkOut - more resources